| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2019-03-08 |
| タイトル |
|
|
タイトル |
Trends in neoadjuvant chemotherapy use and oncological outcomes for muscle-invasive bladder cancer in Japan: a multicenter study |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Anan, Go
Hatakeyama, Shingo
Fujita, Naoki
Iwamura, Hiromichi
Tanaka, Toshikazu
Yamamoto, Hayato
Tobisawa, Yuki
Yoneyama, Tohru
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Koie, Takuya
Ito, Hiroyuki
Yoshikawa, Kazuaki
Kawaguchi, Toshiaki
Sato, Makoto
Ohyama, Chikara
|
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Urol |
| 著者所属 |
|
|
値 |
Tohoku Med & Pharmaceut Univ, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Adv Transplant & Regenerat Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Adv Transplant & Regenerat Med |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Urol |
| 著者所属 |
|
|
値 |
Aomori Rosai Hosp, Dept Urol |
| 著者所属 |
|
|
値 |
Mutsu Gen Hosp, Dept Urol |
| 著者所属 |
|
|
値 |
Aomori Prefectural Cent Hosp, Dept Urol |
| 著者所属 |
|
|
値 |
Tohoku Med & Pharmaceut Univ, Dept Urol |
| 著者所属 |
|
|
値 |
Hirosaki Univ, Grad Sch Med, Dept Urol |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objective: Despite benefits of neoadjuvant chemotherapy (NAC), the adoption of guideline recommendations for NAC use in patients with muscle-invasive bladder cancer (MIBC) has been slow. We aimed to evaluate temporal trends in NAC use and oncological outcomes in a representative cohort of patients with MIBC.
Methods: We included 532 patients from 4 hospitals who underwent radical cystectomy (RC) for >= cT2 MIBC in 1996-2017. We retrospectively evaluated temporal changes in NAC use and progression-free and overall survival. Candidates for NAC were administered with either cisplatin- or carboplatin-based regimens. The impact of NAC on oncological outcomes was examined using multivariate Cox regression analysis with inverse probability of treatment weighting (IPTW) models.
Results: Of 532 patients, 336 underwent NAC followed by RC (NAC group) and 196 underwent RC alone (Ctrl group). NAC use significantly increased from 10% (1996-2004) to 83% (2005-2016). The number of patients administered with cisplatin- and carboplatin-based regimens was 43 and 280, respectively. Oncological outcomes in the NAC group were significantly improved compared to those in the Ctrl group. Multivariable analysis with IPTW models revealed that NAC significantly improved oncological outcomes in patients with MIBC. A nomogram for 5-year overall survival predicted 16% improvement in patients undergoing NAC.
Conclusions: NAC use for MIBC increased after 2005. Platinum-based NAC for MIBC potentially improves oncological outcomes. |
| 書誌情報 |
ONCOTARGET
巻 8,
号 49,
p. 86130-86142,
発行日 2017-10-17
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1949-2553 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.18632/oncotarget.20991 |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 資源タイプ |
|
|
値 |
Article |
oncotarget-86130 (3.0 MB)
